IL141160A0 - A pharmaceutical composition containing a precursor of uric acid - Google Patents

A pharmaceutical composition containing a precursor of uric acid

Info

Publication number
IL141160A0
IL141160A0 IL14116099A IL14116099A IL141160A0 IL 141160 A0 IL141160 A0 IL 141160A0 IL 14116099 A IL14116099 A IL 14116099A IL 14116099 A IL14116099 A IL 14116099A IL 141160 A0 IL141160 A0 IL 141160A0
Authority
IL
Israel
Prior art keywords
uric acid
precursor
pharmaceutical composition
composition containing
biological modifier
Prior art date
Application number
IL14116099A
Other languages
English (en)
Original Assignee
Hme Entpr Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hme Entpr Llc filed Critical Hme Entpr Llc
Publication of IL141160A0 publication Critical patent/IL141160A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/78Polymers containing oxygen of acrylic acid or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14116099A 1998-07-31 1999-08-02 A pharmaceutical composition containing a precursor of uric acid IL141160A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12718498A 1998-07-31 1998-07-31
PCT/US1999/017463 WO2000006171A1 (en) 1998-07-31 1999-08-02 Antioxidant composition and method of treating diseases using same

Publications (1)

Publication Number Publication Date
IL141160A0 true IL141160A0 (en) 2002-02-10

Family

ID=22428746

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14116099A IL141160A0 (en) 1998-07-31 1999-08-02 A pharmaceutical composition containing a precursor of uric acid
IL141160A IL141160A (en) 1998-07-31 2001-01-29 Pharmaceutical composition containing a precursor of uric acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL141160A IL141160A (en) 1998-07-31 2001-01-29 Pharmaceutical composition containing a precursor of uric acid

Country Status (9)

Country Link
EP (1) EP1100507B1 (ja)
JP (1) JP2002521451A (ja)
AT (1) ATE352306T1 (ja)
AU (1) AU5250799A (ja)
CA (1) CA2339004C (ja)
DE (1) DE69934987T2 (ja)
ES (1) ES2279627T3 (ja)
IL (2) IL141160A0 (ja)
WO (1) WO2000006171A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696485B1 (en) 1996-04-02 2004-02-24 Mars, Incorporated Procyanidin and cyclo-oxygenase modulator compositions
CN100548304C (zh) 2000-03-22 2009-10-14 马尔斯公司 应用与乙酰水杨酸联合的可可矢车菊苷配质作为抗血小板疗法
CA2304869A1 (en) * 2000-04-07 2001-10-07 Roman Rozencwaig Method of medical treatment using uric acid or precursors thereof
FR2808192A1 (fr) * 2000-04-28 2001-11-02 Oreal Epichatechine comme inhibiteur de no-synthase et utilisations
US6479547B1 (en) * 2000-11-21 2002-11-12 Arthur Vanmoor Method of treating an infection by enhancing the effectiveness of the human immune system
CN1221190C (zh) * 2001-02-09 2005-10-05 新纪元公司 解烟毒组合物和方法
JP2002326922A (ja) * 2001-03-01 2002-11-15 Kose Corp 皮膚外用剤
ITVR20010031A1 (it) * 2001-03-12 2002-09-12 Hisanori Suzuki Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative.
WO2009047639A2 (en) * 2007-07-23 2009-04-16 Keimyung University Industry Academic Cooperation Foundation Epicatechin deficient green tea
KR101694482B1 (ko) * 2009-09-21 2017-01-10 (주)아모레퍼시픽 녹차의 줄기세포를 함유하는 항산화 및 항노화용 화장료 조성물
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
CN105497355A (zh) * 2015-07-23 2016-04-20 四川金堂海纳生物医药技术研究所 一种治疗破伤风的散剂药物及其制备方法
JP7333942B2 (ja) * 2019-06-07 2023-08-28 株式会社スタージェン 神経変性疾患に対するatp増強療法の効果を予測する方法
CN114377124B (zh) * 2021-07-13 2023-08-25 中国医学科学院输血研究所 次黄嘌呤与注射用人免疫球蛋白的联合用药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113162B1 (en) * 1982-09-16 1989-07-19 Hem Research, Inc. Anti-proliferative action of dsnras on tumor cells
JPS60126220A (ja) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc 核酸成分組成物
US5043100A (en) * 1987-07-23 1991-08-27 Rutgers, The State University Of New Jersey Process for manufacture of natural antioxidant products from tea and spent tea
GB8918368D0 (en) * 1989-08-11 1989-09-20 Amco Chemie Gmbh Compositions for treating obstructive airways disease
LU87766A1 (fr) * 1990-07-20 1992-03-11 Oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre
FR2692784B1 (fr) * 1992-06-24 1995-06-30 Pf Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
US5391568A (en) * 1992-07-10 1995-02-21 American Health Foundation Inhibition of lung tumorigenesis by administration of a polyphenol
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
BR9602919A (pt) * 1996-06-27 1999-01-12 Cosmeticos Natural Ind Com Composições cosméticas para o cuidado da pele
AU4699299A (en) * 1998-06-26 2000-01-17 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity

Also Published As

Publication number Publication date
EP1100507B1 (en) 2007-01-24
DE69934987T2 (de) 2007-05-16
EP1100507A1 (en) 2001-05-23
DE69934987D1 (de) 2007-03-15
AU5250799A (en) 2000-02-21
ES2279627T3 (es) 2007-08-16
JP2002521451A (ja) 2002-07-16
ATE352306T1 (de) 2007-02-15
CA2339004C (en) 2008-04-01
EP1100507A4 (en) 2002-07-31
CA2339004A1 (en) 2000-02-10
WO2000006171A1 (en) 2000-02-10
IL141160A (en) 2009-11-18

Similar Documents

Publication Publication Date Title
Chen et al. The antioxidant procyanidin reduces reactive oxygen species signaling in macrophages and ameliorates experimental colitis in mice
IL141160A0 (en) A pharmaceutical composition containing a precursor of uric acid
BR0214772A (pt) sistemas e métodos para o tratamento de pacientes com células lipoaspiradas processadas
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
Grant et al. Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA
DE60027719D1 (de) Krebstherapie
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
WO2003025149A8 (en) Cell populations which co-express cd49c and cd90
EP0696456A3 (de) Kombination von Nekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Therapie von Tumoren und entzündlichen Erkrankungen
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
BR9808109A (pt) Inibidor terapêutico de células vasculares da musculatura lisa
WO2002007722A3 (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
WO2004050033A3 (en) Method of treating cancers
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
NO20050793L (no) Anvendelse av urease for inhibering av kreftcellevekst
CO5590913A2 (es) Terapia de combinacion antivirica
HUP0103112A2 (hu) Glikogén foszforiláz inhibitorok alkalmazása daganatnövekedés gátlására
BR9809284A (pt) Construto e processo para expressão de polinucleotìdeo em altos nìveis
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
Pavithran et al. Nail changes due to docetaxel.
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos
ES2042529T3 (es) Un procedimiento para preparar una composicion terapeutica combinada de un eliminador de radicales libres o inhibidor metabolico y una proteina biologicamente activa.